NASDAQ:ALNAAllena Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allena Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.45 -0.02 (-1.36 %) (As of 07/9/2020 04:00 PM ET) Add Compare Share Today's Range$1.39Now: $1.45▼$1.4850-Day Range$1.46MA: $1.79▼$2.7152-Week Range$0.53Now: $1.45▼$6.30Volume337,571 shsAverage Volume485,627 shsMarket Capitalization$35.88 millionP/E RatioN/ADividend YieldN/ABeta2.89 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAllena Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.60, Allena Pharmaceuticals has a potential upside of 700.0% from its current price of $1.45.Amount of Analyst CoverageAllena Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAllena Pharmaceuticals has received 219 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllena Pharmaceuticals has received 209 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllena Pharmaceuticals has received 51.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllena Pharmaceuticals does not currently pay a dividend.Dividend GrowthAllena Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allena Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Allena Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.65% of the stock of Allena Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allena Pharmaceuticals are expected to grow in the coming year, from ($1.07) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allena Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allena Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllena Pharmaceuticals has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone617-467-4577Debt Debt-to-Equity Ratio0.47 Current Ratio2.84 Quick Ratio2.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book1.99Profitability EPS (Most Recent Fiscal Year)($2.10) Net Income$-47,340,000.00 Net MarginsN/A Return on Equity-189.16% Return on Assets-111.34%Miscellaneous Employees34 Outstanding Shares24,742,000Market Cap$35.88 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:ALNA Rates by TradingView Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions How has Allena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALNA stock has increased by 15.1% and is now trading at $1.45. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allena Pharmaceuticals. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allena Pharmaceuticals. How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) announced its earnings results on Wednesday, May, 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.14. View Allena Pharmaceuticals' earnings history. What price target have analysts set for ALNA? 5 brokerages have issued 1 year price targets for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $26.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $11.60 in the next year. This suggests a possible upside of 700.0% from the stock's current price. View analysts' price targets for Allena Pharmaceuticals. Has Allena Pharmaceuticals been receiving favorable news coverage? Headlines about ALNA stock have been trending somewhat negative recently, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news about Allena Pharmaceuticals. Are investors shorting Allena Pharmaceuticals? Allena Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 435,000 shares, an increase of 48.0% from the June 15th total of 293,900 shares. Based on an average daily volume of 649,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 2.0% of the shares of the company are short sold. View Allena Pharmaceuticals' Current Options Chain. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include Erytech Pharma (ERYP), Solid Biosciences (SLDB), X4 Pharmaceuticals (XFOR), La Jolla Pharmaceutical (LJPC), Outlook Therapeutics (OTLK), Champions Oncology (CSBR), Ayala Pharmaceuticals (AYLA), Gamida Cell (GMDA), Creative Realities (CRDF), Windtree Therapeutics (WINT), Organovo (ONVO), AIM ImmunoTech (AIM), Idera Pharmaceuticals (IDRA), Genocea Biosciences (GNCA) and INmune Bio (INMB). View all competitors. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Exelixis (EXEL), Matinas BioPharma (MTNB), Opko Health (OPK), Amarin (AMRN) and Pieris Pharmaceuticals (PIRS). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the following people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $1.45. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $35.88 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is www.allenapharma.com. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
